

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



mk

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/25, C07K 14/545, 16/24, A61K 38/20, A61P 29/00, 37/04		A1	(11) International Publication Number: WO 00/11174 (43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/US99/18771 (22) International Filing Date: 20 August 1999 (20.08.99) (30) Priority Data: 60/097,413 21 August 1998 (21.08.98) US 60/098,595 31 August 1998 (31.08.98) US 60/099,974 11 September 1998 (11.09.98) US (71) Applicant (for all designated States except US): IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SIMS, John, E. [US/US]; 4207 43rd Avenue N.E., Seattle, WA 98105 (US). SMITH, Dirk, E. [US/US]; 11633 Meadowmeer Circle, N.E., Bainbridge Island, WA 98110 (US). (74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: HUMAN IL-1 EPSILON DNA AND POLYPEPTIDES			
<p>NAME: Human IL-1 epsilon polypeptide</p> <p>Translation in relevant reading frame (5' 3'):</p> <p>EKDIMDLYNQ PEPVKSFLEY HSQSGRNSTF ESVAFPGWFI AVSSEGGCPL ILTQELGKAN TTDFGLTMLF * (SEQ ID NO:6)</p> <p>MEKALKIDTP QGSIQDINH RVWVLQDQTL IAVPRKDRMS PVTIALISCR HVETLEKDRG NPIYLGGLNGL NLCLMCAKVG DQPTLQLKEK DIMDLYNQPE PVKSFLFYHS QSGRNSTFES VAFPGWFIAV SSEGGCPLIL TQELGKANTT DFGLTMLF* (SEQ ID NO:8)</p> <p>MEKALKIDTP ORGSIQDINH RVWVLQDQTL IAVPRKDRMS PVTIALISCR HVETLEKDRG NPIYLGGLNGL NLCLMCAKVG DQPTLQLKEK DIMDLYNQPE PVKSFLFYHS QSGRNSTFES VAFPGWFIAV SSEGGCPLIL TQELGKANTT DFGLTMLF* (SEQ ID NO:13)</p>			
(57) Abstract			
<p>The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.</p>			